DET1 partner of COP1 E3 ubiquitin ligaseGenealiases: []
Q-omics provides the consensus-scored DET1 profile across patient tissues and cancer cell-line models. DET1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DET1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, DET1 RNA expression shows 21,122 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where DET1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DET1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DET1 survival associations across molecular data types. DET1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DET1 RNA expression–survival associations across cancer types. High DET1 expression shows unfavorable associations in SCLC, but favorable associations in KIRC, UVM, UCS, BRCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DET1 RNA expression.
This table summarizes DET1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DET1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DET1 shows lower tumor expression in THCA, UCEC, KIRP and BRCA and higher tumor expression in LIHC and CHOL. The THCA box plot shows higher DET1 RNA expression in normal versus tumor tissue (log2 FC = −0.606, t-test p < 0.001).
This table shows molecular features associated with DET1 in patient tissues and cancer cell lines. In patient samples, DET1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DET1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
